Trial Profile
A multicentre open-label phase IIa study with escalating dose of MS1819-SD, to investigate the efficacy and safety of a Yarrowia lipolytica lipase preparation for the compensation of exocrine pancreatic insufficiency caused by chronic pancreatitis and/or distal pancreatectomy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Adrulipase alfa (Primary)
- Indications Exocrine pancreatic insufficiency
- Focus Adverse reactions; First in man
- Sponsors AzurRx BioPharma
- 18 Mar 2019 According to the AzurRx BioPharma media release, data will be presented at the 2019 Digestive Disease Week (DDW) Conference.
- 24 Sep 2018 According to the AzurRx BioPharma media release, results from this study are expected to be present an upcoming major medical meeting.
- 24 Sep 2018 Results presented in an AzurRx BioPharma media release